GLP-1 Coverage at Renewal: Cover, Control, or Cut?

This site contains affiliate links. View the disclosure for more information.

Employers have three real options for GLP-1 weight-loss coverage at renewal: cover with guardrails, cover for diabetes only, or cut weight-loss coverage entirely. The right answer depends on your claims data, your stop-loss contract, and your population — not on what the company down the street did. Here’s how to actually decide.

Your renewal packet is going to land sometime between now and October, and there’s a decent chance one line inside it explains most of the increase: pharmacy. And inside pharmacy, one drug class: GLP-1s.

Here’s the thing I keep seeing, and it’s the thing that worries me for small and midsize admins. The broker presents the renewal number, the GLP-1 spend sits buried as one line in a claims summary, leadership panics at the total, and the coverage decision gets made in a rushed meeting two weeks before open enrollment materials are due. That’s how you end up with a decision nobody modeled and an employee communication nobody planned.

You own this plan. So let’s slow it down and make the decision like an owner.

Why are GLP-1s blowing up your renewal?

Chart graphic showing GLP-1 medications’ rising share of employer health plan pharmacy claims driving 2026 renewal increases — About 10.5% of pharmacy claims and climbing. That’s your renewal line.

Because demand exploded and the price didn’t drop. These drugs list at over $1,000 a month before rebates (Mercer, 2026), and they’re built for long-term use — which makes them some of the most expensive chronic medications a plan can carry.

The 2026 numbers, dated and sourced, since these move every year:

Employer health costs are projected to rise 6.7% in 2026, to about $18,500 per employee on average — even after planned cost cuts (Mercer).
GLP-1s made up about 10.5% of annual pharmacy claims in 2025, up from 6.9% in 2023 (International Foundation of Employee Benefit Plans).
Modeling shows broad GLP-1 weight-loss coverage can raise employer premiums 6% to nearly 14% a year (Employee Benefit Research Institute).
As of 2026, 67% of surveyed large employers cover GLP-1s for weight management — but only 72% expect to keep that coverage in 2027, meaning roughly one in ten are already planning to drop it. (Business Group on Health).

One more thing worth knowing before you decide: this isn’t purely a cost story. Aon’s 2026 claims analysis found employees with type 2 diabetes on sustained GLP-1 therapy showed about 6% lower medical cost growth after 30 months. There’s a real long-game argument for coverage. It just has to survive your short-game budget.

What are your actual options?

Three lanes. Every vendor pitch and broker deck is a variation of one of these.

Option 1 — Cover for weight loss, with guardrails

You keep the benefit but control who qualifies and how. The standard guardrails: prior authorization tied to clinical criteria (like BMI thresholds and documented conditions), step therapy that requires lower-cost options first, and required participation in a lifestyle or care-management program alongside the prescription.

Best fit: employers who see recruitment and retention value in the benefit and have the claims volume to negotiate. The trade: guardrails add friction and denials, and somebody — you — fields those angry calls.

Option 2 — Cover for diabetes only

You cover GLP-1s for their type 2 diabetes indication (which most plans already do) and exclude the weight-loss-only versions. This is the middle lane, and as of 2026 it’s where a lot of carriers are pushing groups by default.

Best fit: employers who need cost relief now but don’t want to touch a medically necessary diabetes benefit. The trade: expect off-label pressure, appeals, and hard conversations with employees who are mid-treatment for weight loss.

Option 3 — Cut weight-loss coverage entirely

Some carriers are making this call for you. Blue Cross Blue Shield of Massachusetts, for example, is ending GLP-1 weight-loss coverage at 2026 renewal for groups under 100, with larger groups choosing whether to buy it back.

Best fit: plans where the spend is genuinely unsustainable and leadership accepts the morale cost. The trade: the employees currently on these medications will feel it personally, and they will remember how it was communicated. If you pick this lane, your communication plan matters as much as the decision.

What’s the stop-loss trap nobody mentions?

If you’re self-funded or level-funded, read your stop-loss contract before you decide anything. As of 2026, some stop-loss carriers are excluding GLP-1 weight-loss claims from counting toward your attachment point — meaning those costs stay 100% yours no matter how high they climb. Others are “lasering” members already on GLP-1 therapy at renewal, setting a higher individual threshold just for them.

Translation: you might believe you have catastrophic protection on this spend, and you might not. Ask your broker to pull the exact contract language and show you any GLP-1-specific provisions. If there’s a carve-out, your real exposure is bigger than your renewal deck says.

What do you ask your broker before you decide?

Bring this list to the renewal meeting. In writing.

“Break out our GLP-1 pharmacy claims by indication.” Diabetes versus weight loss, separately. If they can’t split it, ask the PBM to. You can’t decide on a number you can’t see.
“Show me the stop-loss language on GLP-1s.” Carve-outs, lasers, attachment point exclusions. Exact wording.
“Model all three options against our actual claims.” Cover-with-guardrails, diabetes-only, and full exclusion — with the premium impact of each.
“What are the rebate assumptions?” List price and net price on GLP-1s are very different numbers. Make sure the model uses the real one.

“What’s the utilization management vendor actually charging?” Some guardrail programs cost enough to eat the savings. Get the fee next to the projection

Where do you start?

Request the GLP-1 claims breakout today. Don’t wait for the renewal packet — the earlier you see the number, the more options you have.
Read your stop-loss contract’s pharmacy provisions (self-funded and level-funded plans).
Whatever you decide, plan the employee communication now. A coverage change at OE with no warning is how trust dies. My free “Steal My Open Enrollment Emails” toolkit gives you the exact email framework for delivering plan changes without the panic. → OE Emails Freebie
If your team wants a practitioner to pressure-test the whole decision — the claims data, the renewal math, the communication plan — that’s exactly what my Benefits Operations Audit does. Email me at ekirby@ericakirby.com and tell me where your renewal stands.

REAL TALK

Nobody told me that the hardest part of a renewal isn’t the math. It’s that every line in that spreadsheet is somebody’s Tuesday. Whatever you decide on GLP-1s, there are employees on your plan taking these medications right now, and they’ll learn about your decision in an email with your name on it. You own the plan, which means you own the communication too. Decide deliberately, communicate early, and never let a coverage change be a surprise.

This is the plain-English version to get you oriented — not legal or tax advice. Before you act on any of it, confirm the specifics with your broker, your benefits counsel, or your filing software. My job here is to make it make sense, not to be your lawyer.

FAQ

Q: Do employers have to cover GLP-1s for weight loss? A: No. As of 2026, GLP-1 weight-loss coverage is an employer plan design choice, not a mandate. Coverage for the type 2 diabetes indication is standard on most plans, but weight-loss coverage varies widely and some carriers are removing it at renewal.

Q: How much do GLP-1s cost an employer health plan? A: These drugs list at over $1,000 per month before rebates, and as of 2025 they made up about 10.5% of annual pharmacy claims across many employer plans. Modeling shows broad weight-loss coverage can raise premiums 6% to nearly 14% a year.

Q: Can we cover GLP-1s for diabetes but not weight loss? A: Yes. Indication-based coverage — covering the diabetes-approved versions while excluding weight-loss-only versions — is one of the most common 2026 cost-control designs. Expect appeals and off-label pressure, and plan your employee communication carefully.

Q: What is stop-loss lasering on GLP-1s? A: Lasering is when a stop-loss carrier sets a higher individual reimbursement threshold for a specific member — including members already on GLP-1 therapy at renewal. Some carriers also exclude GLP-1 weight-loss claims from the attachment point entirely, leaving that cost fully with the employer.